Compare TSLX & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | OCUL |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2011 | 2014 |
| Metric | TSLX | OCUL |
|---|---|---|
| Price | $18.54 | $8.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $21.72 | ★ $22.90 |
| AVG Volume (30 Days) | 1.5M | ★ 7.6M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | N/A | ★ $1,990,000.00 |
| Revenue This Year | N/A | $9.35 |
| Revenue Next Year | $1.92 | $92.88 |
| P/E Ratio | $10.08 | ★ N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $16.99 | $6.23 |
| 52 Week High | $25.17 | $16.44 |
| Indicator | TSLX | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 40.76 |
| Support Level | $16.99 | $8.36 |
| Resistance Level | $22.46 | $12.20 |
| Average True Range (ATR) | 0.57 | 0.67 |
| MACD | 0.12 | -0.11 |
| Stochastic Oscillator | 83.52 | 2.11 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.